163 related articles for article (PubMed ID: 31004381)
21. Cyclophosphamide-containing regimen (TCD) is superior to melphalan-containing regimen (MPT) in elderly multiple myeloma patients with renal impairment.
Song MK; Chung JS; Shin HJ; Moon JH; Lee JJ; Yoon SS; Kim JS; Lee JO; Do YR; Lee HS; Park EK;
Ann Hematol; 2012 Jun; 91(6):889-96. PubMed ID: 22237937
[TBL] [Abstract][Full Text] [Related]
22. Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression.
Jung SH; Choi HJ; Shin MG; Lee SS; Hwang EC; Jung TY; Cho MS; Yang DH; Ahn JS; Kim YK; Kim HJ; Lee JJ
Ann Hematol; 2016 Oct; 95(10):1645-51. PubMed ID: 27365142
[TBL] [Abstract][Full Text] [Related]
23. Current treatments for renal failure due to multiple myeloma.
Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Pharmacother; 2016 Nov; 17(16):2165-2177. PubMed ID: 27646819
[TBL] [Abstract][Full Text] [Related]
24. Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.
Dimopoulos M; Weisel K; van de Donk NWCJ; Ramasamy K; Gamberi B; Streetly M; Offidani M; Bridoux F; de la Rubia J; Mateos MV; Ardizzoia A; Kueenburg E; Collins S; Di Micco A; Rosettani B; Li Y; Bacon P; Sonneveld P
J Clin Oncol; 2018 Jul; 36(20):2035-2043. PubMed ID: 29394124
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange.
Costa LJ; Abbas J; Ortiz-Cruz KL; Kang Y; Stuart RK
Eur J Haematol; 2012 Nov; 89(5):432-4. PubMed ID: 22971164
[No Abstract] [Full Text] [Related]
26. [The Efficacy and Safety of Daratumumab-Based Regimen in Treatment of Multiple Myeloma Patients with Renal Impairment].
Yin LL; Shen YL; Min FL; Gu WY; Wang Y; Qi KM; Li ZY; Xu KL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):141-147. PubMed ID: 36765491
[TBL] [Abstract][Full Text] [Related]
27. Outcome of patients with multiple myeloma and renal failure on novel regimens.
Soleymanian T; Soleimani A; Musavi A; Mojtahedi K; Hamid G
Saudi J Kidney Dis Transpl; 2016 Mar; 27(2):335-40. PubMed ID: 26997388
[TBL] [Abstract][Full Text] [Related]
28. [Clinical Features and Response to Treatment in Newly Diagnosed Multiple Myeloma Patients with Deletion 17P].
Liu Y; Ke XY; Wang J; Wang YF; Dong F; Tian L; Wan W; Jing HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):802-806. PubMed ID: 28641639
[TBL] [Abstract][Full Text] [Related]
29. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E
Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386
[TBL] [Abstract][Full Text] [Related]
30. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients.
Kleber M; Ihorst G; Deschler B; Jakob C; Liebisch P; Koch B; Sezer O; Engelhardt M
Eur J Haematol; 2009 Dec; 83(6):519-27. PubMed ID: 19614956
[TBL] [Abstract][Full Text] [Related]
31. Current treatments for renal failure due to multiple myeloma.
Kastritis E; Terpos E; Dimopoulos MA
Expert Opin Pharmacother; 2013 Aug; 14(11):1477-95. PubMed ID: 23705905
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib-based treatment for multiple myeloma patients with renal impairment: A systematic review and meta-analysis of observational studies.
Zhu W; Chen W
Medicine (Baltimore); 2016 Nov; 95(46):e5202. PubMed ID: 27861343
[TBL] [Abstract][Full Text] [Related]
33. The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study.
Oortgiesen BE; Azad R; Hemmelder MH; Kibbelaar RE; Veeger NJGM; de Vries JC; van Roon EN; Hoogendoorn M
Haematologica; 2018 Jul; 103(7):e311-e314. PubMed ID: 29545339
[No Abstract] [Full Text] [Related]
34. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma.
Gonsalves WI; Leung N; Rajkumar SV; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Kapoor P; Go RS; Lin Y; Russell SJ; Lust JA; Zeldenrust S; Kyle RA; Gertz MA; Kumar SK
Blood Cancer J; 2015 Mar; 5(3):e296. PubMed ID: 25794132
[TBL] [Abstract][Full Text] [Related]
35. Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment.
Lee SR; Choi H; Lee BH; Kang KW; Yu ES; Kim DS; Park Y; Choi CW; Kim BS; Sung HJ
Korean J Intern Med; 2019 Nov; 34(6):1333-1346. PubMed ID: 30360024
[TBL] [Abstract][Full Text] [Related]
36. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment.
Dimopoulos MA; Christoulas D; Roussou M; Kastritis E; Migkou M; Gavriatopoulou M; Matsouka C; Mparmparoussi D; Psimenou E; Grapsa I; Efstathiou E; Terpos E
Eur J Haematol; 2010 Jul; 85(1):1-5. PubMed ID: 20192988
[TBL] [Abstract][Full Text] [Related]
37. [Clinical characteristics and therapeutic efficacy of immunoglobin D multiple myeloma].
Liu Y; Ke XY; Wang J; Jing HM; Wang JJ; Dong F; Wan WL; Zhang W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1628-32. PubMed ID: 25543487
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.
Stork M; Sandecká V; Boichuk I; Adam Z; Krejci M; Brozova L; Sevcikova S; Pour L
Klin Onkol; 2019; 32(6):445-452. PubMed ID: 31842563
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of immunophenotypic complete response in patients with multiple myeloma achieving better than complete response.
Fukumoto K; Fujisawa M; Suehara Y; Narita KT; Usui Y; Takeuchi M; Matsue K
Leuk Lymphoma; 2016 Aug; 57(8):1786-92. PubMed ID: 26764045
[TBL] [Abstract][Full Text] [Related]
40. Analysis of clinical features, treatment response, and prognosis among 61 elderly newly diagnosed multiple myeloma patients: a single-center report.
An N; Li X; Shen M; Chen S; Huang Z
World J Surg Oncol; 2015 Aug; 13():239. PubMed ID: 26245342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
